The present disclosure provides for compounds including retinoid X receptor (RXR) agonists (also known as rexinoids), pharmaceutical compositions including rexinoids, methods of use of the rexinoids and the pharmaceutical compositions, and the like. Compounds and pharmaceutical compositions of the present disclosure can be used in combination with one or more other therapeutic agents for treating different conditions of the eye.
C07C 57/42 - Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings having unsaturation outside the rings
Arizona Board of Regents on Behalf of the University of Arizona (USA)
The UAB Research Foundation (USA)
Inventor
Bibb, James
Umfress, Alan
Abstract
A model and testing device for creating repetitive, rotational head trauma in rodents is disclosed herein. The testing device induces angular rotational acceleration and deceleration forces that result in injury or insult to the integrity of the intracranial tissues of the brain for the test animal and can be used to characterize, test the effects of, and/or investigate a therapeutic agent for rotational traumatic brain injury. In some embodiments, the testing device contains an animal restraint that is configured to secure the animal therein, while allowing the animal's head to rotate about the coronal plane during and following impact. The testing device can include an animal restraint, a restraint mount, configured to receive the animal restraint, a helmet assembly attached to the subject restraint mount, such that the helmet assembly is in pivotal rotation about a central axis of rotation, a pendulum arm, and an impact fixture.
The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the LDHA gene, as well as methods of inhibiting expression of LDHA, methods of inhibiting LDHA and HAO1, and methods of treating subjects that would benefit from reduction in expression of LDHA, such as subjects having an oxalate pathway-associated disease, disorder, or condition, using such dsRNA compositions.
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
4.
POLYMER-PROTEIN CONJUGATE, PHARMACEUTICAL COMPOSITION COMPRISING SAID CONJUGATE, THERAPEUTIC USE THEREOF
The present disclosure provides for compounds including bioactive proteins conjugated with biocompatible polymers to form polymer-protein conjugates. The disclosure also provides for pharmaceutical compositions including the polymer-protein conjugates, methods of use of the polymer-protein conjugates and their pharmaceutical compositions, methods of making the polymer-protein conjugates, and the like.
The present disclosure describes system and methods for determining cardiac events from a physiological data signal and optionally constructing a Pressure-Volume (PV) loop display from non-simultaneously acquired measurements of pressure and volume data. One such method comprises obtaining, by a computing device, a physiological data signal of a heart of an individual; identifying, by the computing device, features of the physiological data signal and applying the features as inputs to a prediction model; determining, by the computing device using the prediction model, the cardiac events for one or more valves of the heart, wherein the cardiac events include timing of opening and closing of the one or more valves of the heart; and outputting, by the computing device, the cardiac events determined using the prediction model. The physiological data signal can be combined with non-simultaneously acquired volume data to create a PV loop display.
Disclosed is a method for reducing metastasis and/or tumor growth in a subject with cancer by administering an effective amount of an inhibin antibody to the subject with cancer. In particular, the subject may have ovarian cancer and the administration of inhibin antibody may impair tumor growth.
Methods for using BMP9 or an agonist thereof to reduce metastasis of cancer are disclosed. The method may include administering an effective amount of BMP9 or an agonist thereof to a subject in need thereof, to reduce metastasis of cancer. The subject may be a human.
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (USA)
THE UAB RESEARCH FOUNDATION (USA)
Inventor
Bibb, James
Gupta, Priyanka
Carter, Angela
Abstract
Improved antibodies for detection of phosphorylated RBL1, H1.5, LARP6, SUV39H1, and FAM53C have been developed. Assays using them to detect the biomarkers: P-T143 FAM53C, P-T202 LARP6, P-S988 RBL1, P-S17 H1.5, and P-S391 SUV39H1, and diagnostic and prognostic applications stemming therefrom are also provided.
G01N 33/537 - ImmunoassayBiospecific binding assayMaterials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
A61K 31/335 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
A61K 31/34 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, the disclosure, in one aspect, relates to compounds that are voltage-gated sodium channel (VGSC) inhibitors, pharmaceutical compositions including VGSC inhibitors, methods of use of the VGSC inhibitors and the pharmaceutical compositions, methods of making VGSC inhibitors, and the like. Compounds and pharmaceutical compositions of the present disclosure can be used in combination with one or more other therapeutic agents for treating metastatic cancers, medullary thyroid cancer, metastatic medullary thyroid cancer, chronic pain, and other diseases.
The present disclosure is directed to compositions and methods for the generation of S-nitrosoacetylcysteine (SNOAC) for stable administration in the improvement, treatment and/or prevention of conditions that benefit from increased bioavailable nitric oxide. The present methods allow generation and delivery of SNOAC through various administration routes, including sublingually, orally, and through inhalation of aerosolized formulations. SNOAC is generated through a reaction between N-acetylcysteine and a nitrite compound in an aqueous medium.
Uses of soluble α-klotho (sKL) to reduce the activity of FGF23 are described. Because FGF23 is implicated in numerous pathologies of humans and other animals, sKL can be used to treat and prevent such pathologies. Other applications of sKL in pharmaceuticals, modulating FGF23 activity, and modulating hypertrophy in cardiac myocytes are described. The disclosure also describes nucleic acids encoding sKL, their complements, vectors for such nucleic acids, and genetically modified organisms containing such nucleic acids.
A method of treating a central nervous system cancer in a subject comprising administering to the subject a preconditioning agent, and, administering to the subject a therapeutic dose of an oncolytic virus; wherein the preconditioning agent is an immunostimulant selected from the group consisting of a toll-like receptor agonist, a subtherapeutic dose of an oncolytic virus, and/or an interferon that induces a transient anti-viral response and/or upregulates an interferon response; and wherein the preconditioning agent and the therapeutic dose of the oncolytic virus is administered to the subject's cerebrospinal fluid or periependymal region. Provided herein are methods of treating a central nervous system cancer in a subject. This method allows for intrathecal administration of oncolytic virus, which, until the present invention, resulted in unacceptable toxicity.
The Trustees of the University of Pennsylvania (USA)
Inventor
Maloney, David J.
Waterson, Alex Gregory
Bantukallu, Ganesh Rai
Brimacombe, Kyle Ryan
Christov, Plamen
Dang, Chi V.
Darley-Usmar, Victor
Hu, Xin
Jadhav, Ajit
Jana, Somnath
Kim, Kwangho
Kouznetsova, Jennifer L.
Moore, William J.
Mott, Bryan T.
Neckers, Leonard M.
Simeonov, Anton
Sulikowski, Gary Allen
Urban, Daniel Jason
Yang, Shyh Ming
Abstract
Provided is a compound of formula (I)
Provided is a compound of formula (I)
in which Ar1, R1, U, V, W, X, and p are as described herein. Also provided are methods of using a compound of formula (I), including a method of treating cancer, a method of treating a patient with cancer cells resistant to an anti-cancer agent, and a method of inhibiting lactate dehydrogenase A (LDHA) and/or lactate dehydrogenase B (LDHB) activity in a cell.
A61K 31/4155 - 1,2-Diazoles not condensed and containing further heterocyclic rings
A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
A61K 31/422 - Oxazoles not condensed and containing further heterocyclic rings
A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/5355 - Non-condensed oxazines containing further heterocyclic rings
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 409/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
Disclosed herein is a diagnostic / screening / biomarker tool that can rapidly and safely implemented in clinics to characterize those stoneformers with alanine : glyoxylate aminotransferase (AGT) deficiency (genetically or functionally). Also disclosed are methods of diagnosing and treating calcium oxalate (CaOx) stone disease in subjects with detected AGT deficiency.
Disclosed herein are lipid signaling pathways that can be targeted to prevent or delay the onset of type 1 diabetes (T1D). In particular, disclosed herein a pathway that can be modulated by a chemical inhibitor. Utilizing this inhibitor, evidence was generated suggesting that it is beneficial in reducing the incidence of T1D.
A61K 31/64 - Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
A61K 31/4468 - Non-condensed piperidines, e.g. piperocaine having a nitrogen atom directly attached in position 4, e.g. clebopride, fentanyl
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
19.
Bacteria and Herbal Extract Nutraceutical Blends for Lung Health Maintenance
A combination of herbal extracts and a probiotic supplement and formulated as a dietary supplement helps mitigate symptoms of bronchopulmonary disease in conjunction with the anti-inflammatory mechanisms of the probiotics. Provided are embodiments of a probiotic nutraceutical composition that delivers 3 strains of Lactobacillus spp. to the gut lining of human subjects to reduce neutrophilic inflammation as a result of or causative agent of bronchopulmonary disease. In addition to the three Lactobacillus spp. strains, the compositions can include herbal extracts from holy basil, turmeric, and vasaka for respiratory relief.
The present disclosure is concerned with pyrazolopyrimidine compounds for the treatment of conditions associated with BRIM, RIPK3, and/or IL6 signaling dysfunction such as, for example, cancer (e.g., lung cancer, skin cancer, bladder cancer, kidney cancer, liver cancer), arsenicosis, arsenic poisoning, inflammation, skin lesions, dysfunction of systemic organs, and skin blisters. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
C07D 487/02 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups in which the condensed system contains two hetero rings
The present disclosure is concerned with piperidinedione compounds, pharmaceutical compositions comprising the compounds, and methods of treating disorders associated with the presence of a premature termination codon such as, for example, cystic fibrosis, Duchenne muscular dystrophy, aniridia, Becker muscular dystrophy, spinal muscular atrophy, Hurler syndrome, hemophilia, epidermolysis bullosa (e.g., dystrophic (DEB) form, junctional (JEB) form), Usher syndrome, and cancer, using the compounds. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
The Board of Regents of the University of Texas System (USA)
Inventor
Ilyas, Adeel
Bankim Behari Pati, Sandipan
Abstract
The present disclosure describes various embodiments of systems, apparatuses, and methods for predicting an onset of a seizure by identifying a pro-octal state in advance of the seizure, potentially hours prior to seizure onset. One such method comprise acquiring, by a computing device, electroencephalography (EEG)-based features from brain activity electrical recordings of an individual; inputting, by the computing device, the EEG-based features into a deep neural network-based classifier; classifying, by the computing device using the deep neural network-based classifier, the EEG-based features to a real-valued principal dimension; and/or based on a value of the real-valued principal dimension, generating, by the computing device, a prediction of a seizure onset pro-ictal event.
A61B 5/374 - Detecting the frequency distribution of signals, e.g. detecting delta, theta, alpha, beta or gamma waves
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
23.
BIOMARKERS AND METHODS FOR ASSESSING MYOCARDIAL INFARCTION AND SERIOUS INFECTION RISK IN RHEUMATOID ARTHRITIS PATIENTS
Provided herein are methods for assessing risk of infection or cardiovascular disease (CVD) in a subject with an inflammatory disease, e.g., rheumatoid arthritis. The methods include performing immunoassays to generate scores based on quantitative data for expression of biomarkers relating to inflammatory biomarkers with or without additional clinical variables to assess infection and CVD risk. Also provided are uses of inflammatory biomarkers for guiding treatment decisions.
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
The present disclosure relates to systems and methods for bradycardia prediction and interruption based in part on biomedical signal information received from a sensor positioned on a person. The system can include a computing device in data communication with the sensor. The computing device can receive biomedical signal information from the sensor, including at least heart rate data. The computing device can evaluate a sequence of heart rate values over an interval of time based at least in part on the heart rate data and forecast a predicted heart rate value for a subsequent time. In response to the predicted heart rate value being less than a predetermined threshold value, the computing device can generate an intervention signal to prompt an intervention. The computing device can transmit the intervention signal to an intervention apparatus in communication with the computing device to cause at least a vibration to simulate the person.
G06Q 10/04 - Forecasting or optimisation specially adapted for administrative or management purposes, e.g. linear programming or "cutting stock problem"
Disclosed herein is anti-human CD276 mAb expressing the Fc-fused fragments from the extracellular domain of human CD276 (Leu29-Pro245), producing the N-glycosylated peptides as immunogen, and generating hybridoma cells through fusing mouse splenocytes and myeloma cells. The specific targeting of cancer cells and intracellular release of potent drugs enables high anti-cancer efficiency and minimal side effects.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
The disclosure is based, at least in part, on certain human monoclonal antibodies, or antigen binding fragments thereof, having unexpected broad neutralizing activities against SARS-CoV-2. The disclosed antibodies and/or antigen-binding fragments thereof are therapeutic agents for the treatment of SARS-CoV-2 infections and are suitable for use in therapeutic methods to protect individuals from SARS-CoV-2 infections.
A system can be configured to: (i) obtain a set of input images depicting one or more bodily structures of a patient; (ii) determine whether one or more key structures are represented within the set of input images by utilizing a key structure detection module; (iii) determine one or more key images of the one or more images of the set of input images by utilizing a key image localization module; (iv) determine key structure segmentation by utilizing a key structure segmentation module; (v) determine one or more patient condition metrics using the key structure segmentation; and (vi) generate a report associated with the patient based upon the one or more patient condition metrics, or generate an entry at one or more practitioner worklists based upon the one or more patient condition metrics.
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 40/20 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the management or administration of healthcare resources or facilities, e.g. managing hospital staff or surgery rooms
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
Novel pharmaceutical compositions and method of treating viral respiratory infections using novel sesterterpenoids is presented. The compounds were found to have antiviral activity against viruses such as respiratory syncytial virus.
C07C 35/22 - Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a condensed ring system
The present disclosure provides an improved method for photobleaching an eye of a subject. The disclosed method may be used in a number of psychophysical test methods, including, but not limited to, measurement of dark adaptation. The improved method for photobleaching involves at least one of the following improvements: (i) the use of a bleaching light emitting a particular wavelength of light or a tailored spectrum of wavelengths; (ii) restricting or otherwise spatially tailoring the region of the retina that is subject to photobleaching; and (iii) utilizing a bleaching light having an intensity that is at or below the intensity of ambient daylight. The present disclosure additionally provides a combination of a photobleaching light and an apparatus to administer a psychophysical test suitable for use in practicing the disclosed methods.
A61B 3/06 - Subjective types, i.e. testing apparatus requiring the active assistance of the patient for testing light sensitivity, e.g. adaptationSubjective types, i.e. testing apparatus requiring the active assistance of the patient for testing colour vision
A61B 3/00 - Apparatus for testing the eyesInstruments for examining the eyes
A61B 3/02 - Subjective types, i.e. testing apparatus requiring the active assistance of the patient
A system can be configured to: (i) obtain a set of input images depicting one or more bodily structures of a patient; (ii) determine whether one or more key structures are represented within the set of input images by utilizing a key structure detection module; (iii) determine one or more key images of the one or more images of the set of input images by utilizing a key image localization module; (iv) determine key structure segmentation by utilizing a key structure segmentation module; (v) determine one or more patient condition metrics using the key structure segmentation; and (vi) generate a report associated with the patient based upon the one or more patient condition metrics, or generate an entry at one or more practitioner worklists based upon the one or more patient condition metrics.
Disclosed herein is a method for crossmatching a human subject for porcine transplantation that involves assaying a serum sample from the subject for a swine leukocyte antigen (SLA) haplotype, wherein an SLA haplotype corresponding to a positive control is an indication that the subject is not a crossmatch for the xenotransplantation, and wherein an SLA haplotype corresponding to a negative control is an indication that the subject is a crossmatch for the xenotransplantation.
Disclosed are peptide amphiphiles comprising a hydrophilic peptide sequence and a hydrophobic tail, wherein the hydrophobic tail comprises a moiety having a substituted C16 alkyl chain, wherein the hydrophilic peptide sequence comprises a degrading sequence (DS), wherein the degrading sequence (DS) comprises the amino acid sequence GTAGLIGQ (SEQ ID NO:1) wherein the DS comprises one or more amino acid substitutions. Also disclosed are compositions, liposomes, gels, and medical devices comprising the peptide amphiphiles and methods of use thereof.
Disclosed are peptide amphiphiles comprising a hydrophilic peptide sequence and a hydrophobic tail, wherein the hydrophobic tail comprises a moiety having a substituted C5 alkyl chain, wherein the hydrophilic peptide sequence comprises a nitric oxide producing donor sequence. In some aspects, the hydrophilic peptide sequence comprises a degrading sequence (DS), wherein the degrading sequence (DS) comprises the amino acid sequence GTAGLIGQ (SEQ ID NO:1) wherein the DS comprises one or more amino acid substitutions. Also disclosed are compositions, liposomes, gels, and medical devices comprising the peptide amphiphiles and methods of use thereof.
C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
4Staphylococcus aureusStaphylococcus aureus (MRSA). In one aspect, the compositions can be applied topically in the forms of gels, creams, lotions, sprays, and the like. In any of these aspects, the compositions are non-toxic to mammalian cells. Also disclosed are compositions that can be used to perform the disclosed methods.
The United States Government as Represented by the Department of Veterans Affairs (USA)
Inventor
Suto, Mark J.
Mathew, Bini
Agarwal, Anupam
Traylor, Amie M.
Abstract
The present disclosure is concerned with thioquinolinone compounds for the treatment of disorders associated with heme oxygenase-1 (HO-1) signaling dysfunction such as, for example, kidney diseases (e.g., chronic kidney disease, acute kidney injury). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
C07D 215/40 - Nitrogen atoms attached in position 8
C07D 215/48 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
C07D 217/22 - Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
Intuitive Research and Technology Corporation (USA)
The UAB Research Foundation (USA)
Inventor
Huang, Junjian
Cantor, Chanler Megan Crowe
Thomas, Steven Michael
Abstract
Techniques for evaluating images are disclosed. An image is displayed. Data corresponding to a gaze fixation of a user who is viewing the image is obtained. An image artifact is identified based on the gaze fixation. The image artifact is at a location in the image where the gaze fixation occurred. A recording of the user's utterance is accessed. This recording is recorded during an overlapping time period with when the gaze fixation occurred. The recording is transcribed into text, which is then parsed. A key term is extracted from the parsed text. A determination is made as to whether the key term corresponds to the image artifact identified based on the gaze fixation.
In one aspect, the disclosure relates to pneumococcal vaccines comprising a semisynthetic saponin adjuvant VSA-1. In one aspect, the disclosed vaccines elicit an immune response in a subject that is measurably higher than the response in an otherwise identical subject who receives a vaccine without the semisynthetic saponin adjuvant. In another aspect, the disclosed vaccines are useful across age groups and immunization can be achieved with fewer injections than for standard pneumococcal vaccines. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.
A61K 39/385 - Haptens or antigens, bound to carriers
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
C07K 14/315 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
The present disclosure provide systems and methods for removing electrical stimulus transients from electrophysiological recordings. One such method comprises delivering a single electrical stimulus pulse to electrically excitable tissue; subsequently delivering a pair of electrical stimulus pulses to the electrically excitable tissue, wherein a first of the pair of electrical stimulus pulses is not delivered during an absolute refractory period for the electrically excitable tissue and a second one of the pair of electrical pulses is delivered within the absolute refractory period; acquiring an electrical response to the single electrical stimulus pulse; acquiring an electrical response to the pair of electrical stimulus pulses; determining a template stimulus artifact based on the acquired electrical responses to the single electrical stimulus pulse and the pair of electrical stimulus pulses; and/or isolating a stimulus response from another electrical response by subtracting the template stimulus artifact from the other electrical response.
A61B 5/246 - Detecting biomagnetic fields, e.g. magnetic fields produced by bioelectric currents specially adapted for magnetoencephalographic [MEG] signals using evoked responses
LachnospiraceaeLachnospiraceaeLachnospiraceae flagellin. Also provided is antibody of fragment thereof that binds to one or more of the plurality of the flagellin peptides in the peptide array. The peptide array and antibody are useful in determining an immunosignature from a biological sample from a subject. The immunosignature is useful in diagnosis of an immune-mediated disease, in monitoring progression of an immune-mediated disease, in identifying subjects susceptible to certain treatments, and in monitoring treatment response.
United States Government as Represented by the Department of Veterans Affairs (USA)
Inventor
Slominski, Andrzej T.
Raman, Chander
Quayyum, Shariq
Abstract
The present disclosure provides for pharmaceutical composition and methods of treating a condition using the pharmaceutical composition. The condition to be treated in a subject in need of treatment can include an infection or non-viral hyper-inflammation/immune hyperactivation condition. The infection can be a coronavirus infection, HIV infection, influenza infection, or the like, where a direct or indirect result of the infection can be respiratory distress, oxidative stress, and the like that can lead to acute respiratory distress syndrome (ARDS) and/or organ dysfunction or failure.
A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
A61K 31/57 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
A61K 31/593 - 9,10-Secocholestane derivatives, e.g. cholecalciferol, vitamin D3
Provided herein are Mycobacterium smegmatis porin nanopores, systems that comprise these nanopores, and methods of using and making these nanopores. Such nanopores may be wild-type MspA porins, mutant MspA porins, wild-type MspA paralog porins, wild-type MspA homolog porins, mutant MspA paralog porins, mutant MspA homolog porins, or single-chain Msp porins. Also provided are bacterial strains capable of inducible Msp porin expression.
Various examples are provided related to catalytic nanofiber membrane assemblies or structures which can be used in plasma reactors. In one example, a three-dimensional (3D) catalytic structure includes nanofiber-based elements (NFBEs) and electrodes placed about the NFBEs with the NFBEs stacked between the electrodes. In another example, a plasma reactor includes a vessel containing the 3D catalytic structure where gas pressure in the vessel is less than 1 atmosphere.
C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
45.
SYSTEMS AND METHODS FOR GENERATING HISTORY AND PHYSICAL EXAM NOTES
A method for generating a medical record note comprises (i) accessing a corpus of medical documentation for a particular patient; (ii) receiving, at a user interface, chief complaint input indicating a chief complaint associated with the particular patient; (iii) utilizing (a) the chief complaint and (b) at least a portion of the corpus of medical documentation for the particular patient as input to a set of artificial intelligence (AI) modules, the set of AI modules being trained to generate medical record note output in response to medical documentation input; and (iv) generate a medical record note for the particular patient based on output of the set of AI modules.
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
46.
METHODS FOR CARDIOVASCULAR DISEASE IN RHEUMATOID ARTHRITIS
This invention includes methods for assessing and treating risk of cardiovascular disease (CVD) in a subject with an inflammatory disease, for example rheumatoid arthritis (RA). Provided are methods for assessing risk, for recommending therapy, for prognosis and monitoring, and for treatment, which are advantageously accurate for CVD in RA. The methods include measuring quantitative data for biomarkers, calculating a CVD risk score for a subject using training data, and validating the CVD risk score with a set of validation clinical data.
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
A disposable imaging phantom including a top housing having an inlet, and outlet, and first chamber in communication with the inlet and outlet and a bottom housing having a second chamber. The bottom housing connects to the top housing. The first and second chamber are configured to receive a first fluid. The first chamber is configured to receive a second fluid through the inlet to displace the first fluid through the outlet. The imaging phantom also includes a membrane assembly configured to be positioned between portions of the top and bottom housings. The membrane assembly includes a semi-permeable membrane configured to permit diffusion of the second fluid from the first chamber into the second chamber.
Disclosed herein is a simple and reproducible 3D-culture-based process for generating cardiac spheroids containing all four cardiac-cell types (cardiomyocytes, endothelial cells, smooth muscle cells, and cardiac fibroblasts) that is compatible with a wide range of applications and research equipment. Subsequent experiments demonstrated that the inclusion of vascular cells and cardiac fibroblasts was associated with an increase in spheroid size, a decline in apoptosis, an improvement in sarcomere maturation and a change in CM bioenergetics. These suggest a three-dimensional (3D) environment with endothelial cells, smooth muscle cells, and cardiac fibroblasts which promoted CM maturation and electrical activity.
C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
49.
COMPOSITIONS AND METHODS FOR TREATMENT OF SUBJECTS SUFFERING FROM A SARS-COV-2 INFECTION
The application is directed to methods for treatment or prevention of SARS-CoV-2 infection in a subject in need thereof, the composition comprising an organic acid (e.g., ascorbic acid), glutathione, a glutathione derivative, a glutathione conjugate, a pharmaceutically acceptable salt thereof, and methods of using the same.
The current disclosure provides methods for the production of 'vaccine-like' antiviral preparations. The present disclosure provides compounds for the treatment of a wide range of enveloped viral diseases and conditions. The present disclosure further provides methods for treating, preventing, and/or suppressing an enveloped virus disease in a subject using the compounds disclosed herein as well as pharmaceutical compositions comprising such compound.
A method for co-registering imagery of different modalities includes accessing a first image captured according to a first imaging modality that depicts a plurality of physical markers. The plurality of physical markers is present within a scene represented in the first image. The method includes accessing a second image captured according to a second imaging modality that captures at least a portion of the scene including the plurality of physical markers. The method further includes generating a transformation matrix using the first image data and the second image data and generating an aligned image by applying the transformation matrix to the first image or the second image. The aligned image is combinable with the first image or the second image to generate co-registered image output. The co-registered image output depicts the portion of the scene according to the first imaging modality and the second imaging modality.
A system for determining subject orientation includes a medical imaging sensor configured to capture medical imagery of an imaging subject. The system also includes one or more interoceptive sensors, which are configured to obtain interoceptive sensor data indicative of an orientation associated with the system.
C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
54.
IDENTIFICATION OF NOVEL BENZOTHIAZONES AS TAU-SH3 INTERACTION INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
The present disclosure is concerned with benzothiazone compounds that are capable of inhibiting Tau-SH3 signaling. The present disclosure is also concerned with methods of using these compounds for the treatment of neurological disorders such as, for example, amyotrophic lateral sclerosis (ALS), Alzheimer's disease, epilepsy, autism spectrum disorders, Parkinson's disease, spinal muscular atrophy, traumatic brain injury, vascular dementia, Huntington's disease, mental retardation, and attention deficit and hyperactivity disorder (ADHD). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
C07D 265/36 - 1,4-OxazinesHydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
C07D 279/16 - 1,4-ThiazinesHydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
A61K 31/538 - 1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
A61P 25/14 - Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A surgical tool support system is provided. The system includes a support portion, a swivel arm, and a tool holder for holding a surgical tool coupled to a distal end of the swivel arm. The tool holder can have a locking joint controlled by an actuator such that the tool holder can be locked into a position along multiple axes of rotation. The system can offset the force required by a user to move the surgical tool, thereby reducing fatigue.
The present disclosure is concerned with substituted uracil compounds, pharmaceutical compositions comprising the compounds, and methods of treating disorders associated with the presence of a premature termination codon such as, for example, cystic fibrosis, Duchenne muscular dystrophy, aniridia, Becker muscular dystrophy, spinal muscular atrophy, Hurler syndrome, hemophilia, epidermolysis bullosa (e.g., dystrophic (DEB) form, junctional (JEB) form), Usher syndrome, and cancer, using the compounds. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
57.
SELECTIVE STIMULATION OF GROUPS OF NEURAL ELEMENTS WITHIN A REGION OF THE BRAIN
Symptoms of maladies originating in the same region of a brain can be treated with selective multifrequency stimulation. A first stimulation at a first frequency and a second stimulation at a second frequency can be generated by a signal generator. The first stimulation can be applied to a first location in the brain region to trigger an excitation period for a first set of neural elements in the brain region to treat at least one symptom of the malady. The second stimulation can be applied, after a time to ensure the first set of neural elements has entered a refractory period, to a second location in the brain region to trigger an excitation period for a second set of neural elements in the brain region to treat the at least one symptom and/or at least another symptom. The first set of neural elements is not excited by the second stimulation.
The present disclosure presents wearable sensor apparatuses, systems, and related methods. One such apparatus is in the form of a wearable sensor device that comprises a processor and a plurality of gas sensors integrated on the wearable sensor device, in which the gas sensors measure an amount of NO2, SO2, and O3 present in ambient air. The wearable sensor device further comprises a peak flow meter sensor integrated on the wearable sensor device; a temperature sensor integrated on the wearable sensor device; a GPS sensor integrated on the wearable sensor device; one or more transceivers integrated on the wearable sensor device; and an electronic display, wherein the processor is coupled to the electronic display and is operable to display sensor data measured from the wearable sensor device.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 40/60 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
59.
METHODS RELATING TO DIAGNOSING STABILITY FOLLOWING RENAL TRANSPLANTATION
Clinical detection or diagnosis of transplant rejection currently utilizes various methods that rely on qualitative rather than quantitative data, or quantitative data that has low sensitivity and/or has a high rate of operator error. Provided herein are methods for identifying kidney transplant rejection in patents that is automated and consistent for the user. Further described herein are cut-offs for transplant biomarkers that relate to renal transplantation stability or rejection.
C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
60.
DEVICES AND METHODS FOR TRANSCUTANEOUS BILIRUBIN MEASUREMENT
Wearable devices for measuring health indicators such as bilirubin are provided. The device includes a skin-facing side including a circuit board. The circuit board includes a spectrometer integrated circuit, at least one light emitting diode (LED) configured to direct light at the subject's skin where the LED is operably connected to a power source, at least one photodetector configured to receive light reflected from the subject's skin, and a microcontroller configured to perform spectral subtraction of said reflected light.
G01N 33/72 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving blood pigments, e.g. hemoglobin, bilirubin
A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using optical sensors, e.g. spectral photometrical oximeters
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
61.
TREATING PRIMARY OR IDIOPATHIC HYPEROXALURIA WITH SMALL MOLECULE INHIBITORS OF LACTATE DEHYDROGENASE
The USA, as Represented by the Secretary, Department of Health and Human Service (USA)
Inventor
Hall, Matthew
Urban, Daniel J.
Knight, John
Holmes, Ross
Wood, Kyle David
Waterson, Alex
Darley-Usmar, Victor M.
Neckers, Leonard M.
Abstract
The disclosure provides methods of treating a patient having primary hyperoxaluria or idiopathic hyperoxaluria comprising administering a therapeutically effective amount of compound of the formula
The disclosure provides methods of treating a patient having primary hyperoxaluria or idiopathic hyperoxaluria comprising administering a therapeutically effective amount of compound of the formula
The disclosure provides methods of treating a patient having primary hyperoxaluria or idiopathic hyperoxaluria comprising administering a therapeutically effective amount of compound of the formula
and pharmaceutically acceptable salts, solvates, and hydrates thereof to the patient. The variables, e.g. ring A, n, R, R3, R10, X, Y, and Z are defined herein. These compounds act as lactate dehydrogenase inhibitors and are useful inhibiting the conversion of glyoxylate to oxalate. When administered to a patient having a disease or disorder associated with elevated oxalate levels, such as PH type 1, type 2, or type 3 or idiopathic hyperoxaluria the compounds prevent or substantially reduce the amount and buildup of oxalate the patient's kidneys, bladder, urinary tract and other parts of the patient's body.
A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
62.
METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING INFLAMMATORY SKIN DISORDERS
Provided herein are methods for treating or preventing inflammatory skin disorders, such as Hidradenitis suppurativa, by administering to a subject having or at risk of developing the inflammatory skin disorder an agent that inhibits NK cell activity.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 47/51 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
63.
SAPONIN-BASED IMMUNOSTIMULANTS, PHARMACEUTICAL COMPOSITION COMPRISING SAID IMMUNOSTIMULANTS, THERAPEUTIC USE THEREOF
The present disclosure provides for compounds including modified saponin compounds, pharmaceutical compositions including modified saponin compounds, methods of use of the modified saponin compounds and the pharmaceutical compositions, methods of making modified saponin compounds, and the like. Compounds and pharmaceutical compositions of the present disclosure can be used in combination with one or more other therapeutic agents for treating viral infection and other diseases.
In one aspect, the disclosure relates to a synthetic modified mRNA (modRNA) and a novel gene therapy approach using the same that offers efficient, transient, safe, nonimmunogenic, and controlled mRNA delivery to the heart tissue without any risk of genomic integration. In a further aspect, the disclosure relates to methods of using the modRNA to achieve transient and exclusive overexpression of CCND2 only in cardiomyocytes, increasing cell cycle markers, enhancing cardiac function, and promoting myocardial repair. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
66.
SYSTEMS AND METHODS FOR PREVENTING ERRORS IN MEDICAL IMAGING
A method for preventing wrong-patient errors includes receiving a selection of a current imaging subject. The current imaging subject is selected for a current image acquisition session comprising capturing one or more current images of the current imaging subject utilizing at least a first image sensor system of a first imaging modality. The method includes accessing one or more previous images of a previous imaging subject. The one or more previous images depict the previous imaging subject according to at least a second imaging modality that is different from the first imaging modality. The method includes presenting the one or more previous images on a display system and, in response to determining that the previous imaging subject matches the current imaging subject based upon the one or more previous images, performing the current image acquisition session.
The United States Government as represented by the Department of Veterans Affairs (USA)
Inventor
Suto, Mark J.
Mathew, Bini
Agarwal, Anupam
Traylor, Amie M.
Abstract
The present disclosure is concerned with thioquinolinone compounds for the treatment of disorders associated with heme oxygenase-1 (HO-1) signaling dysfunction such as, for example, kidney diseases (e.g., chronic kidney disease, acute kidney injury). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
C07D 215/40 - Nitrogen atoms attached in position 8
C07D 215/48 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
C07D 217/22 - Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
Provided herein are NO generating systems, methods for generating NO for inhaled therapy, and methods of treating patients in need of inhaled NO. The systems can include a reaction vessel having a headspace for NO accumulation, a NO storage system, and a gas mixing chamber. NO gas generated in the reaction vessel can be delivered to the NO storage system via pressure generated by generation of the NO gas, then the NO gas is mixed with a carrier gas in a gas mixing chamber. NO can be generated at the point of patient delivery.
The present disclosure relates to techniques for anti-myopia visual display therapy using a simulated myopic blur. In one particular aspect, a method is provided that includes obtaining a pattern for a digital image, selecting a color channel of the digital image, applying a blur effect to the color channel that modifies the digital image to have a simulated blur, and providing anti-myopia visual display therapy to a subject using the modified digital image. The therapy comprises: (i) rendering the modified digital image on a display of a computing device within a visual environment of the subject, or (ii) placing the modified digital image within the visual environment of the subject, based on an optimal viewing time.
A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
70.
URACIL DERIVATIVES FOR STIMULATING READ-THROUGH OF PREMATURE TERMINATION CODONS
egg., dystrophic (DEB) form, junctional (JEB) form), Usher syndrome, and cancer, using the compounds. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
The present disclosure relates to a method of detecting airflow obstruction using one or more novel metrics associated with a spirometry reading for a subject. The method includes obtaining spirometry data from a subject, generating a first measurement curve and a second measurement curve based on the obtained data for the subject, performing at least a first curve-fitting on the first measurement curve using a Least Absolute Residuals algorithm to estimate a function which closely approximates the spirometry data for the subject by minimizing a sum of absolute deviation, determining a first metric that describes a rate of volume increase based on the estimated function, comparing the first metric to one or more threshold values, and determining a presence or absence of airflow obstruction for the subject based on the comparison of the first metric to the one or more threshold values.
A61B 5/091 - Measuring volume of inspired or expired gases, e.g. to determine lung capacity
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 20/00 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
72.
CD206 TARGETED PEPTIDE CONJUGATES AND METHODS OF USING THE SAME
CD206 targeted peptide conjugates are provided. Aspects of the conjugates include a CD206 binding peptide conjugated to a label or therapeutic agent. Also provided are methods of using the conjugates, e.g., in diagnostic or therapeutic applications.
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
73.
CHEMICAL-BASED NITRIC OXIDE GAS-GENERATING DRUG DEVICE FOR DELIVERY TO A PATIENT
The present disclosure provides tracking systems and methods. One such method comprises generating a continuous wave signal over a frequency range; applying the continuous wave signal to a reading coil element that is electromagnetically coupled to a sensor array, wherein the sensor array comprises a plurality of sensing resonators tuned at different resonance frequencies, where an output frequency response of the sensor array varies as a function of a location of a target object or a shape of the target object within a coverage area of the sensor array; acquiring frequency spectrum data showing changes in the output frequency response of the sensor array from the reading coil element; and predicting, by a control unit device using machine learning, a location of the target object within the coverage area or a behavior of the target object based on the acquired frequency spectrum data. Other methods and systems are also provided.
G01D 5/14 - Mechanical means for transferring the output of a sensing memberMeans for converting the output of a sensing member to another variable where the form or nature of the sensing member does not constrain the means for convertingTransducers not specially adapted for a specific variable using electric or magnetic means influencing the magnitude of a current or voltage
G06V 10/80 - Fusion, i.e. combining data from various sources at the sensor level, preprocessing level, feature extraction level or classification level
Epileptic seizures cannot be effectively controlled in many patients, thereby necessitating the development of novel therapeutic agents. Activation of the A1 receptor (A1R) by endogenous adenosine is an intrinsic mechanism to self-terminate seizures and protect neurons from excitotoxicity. However, targeting A1R for neurological disorders has been hindered by side effects associated with its broad expression outside the nervous system. Herein, the neural-specific A1R/neurabin/RGS4 complex that dictates A1R signaling strength and response outcome in the brain is targeted. A peptide was developed to block the A1R-neurabin interaction and enhance A1R activity. Anticonvulsant and neuroprotective effects are achieved through enhanced A1R function in response to endogenous adenosine in the brain, thus avoiding side effects associated with A1R activation in peripheral tissues and organs.
A61P 25/00 - Drugs for disorders of the nervous system
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A method of optimizing vehicle mobility performance includes receiving technical parameters for each wheel associated with wheel power of the particular wheel on a particular terrain. The method includes determining an optimal vehicle mobility performance by determining an optimal tire slippage for one wheel based on the set of technical parameters for the wheel and individually determining an optimal tire slippage for another wheel based on the set of technical parameters for the other wheel. A system may utilize such a method to control mobility performance in a vehicle such as, but not limited to, an autonomous ground vehicle.
B60W 40/12 - Estimation or calculation of driving parameters for road vehicle drive control systems not related to the control of a particular sub-unit related to parameters of the vehicle itself
B60W 60/00 - Drive control systems specially adapted for autonomous road vehicles
B60W 40/02 - Estimation or calculation of driving parameters for road vehicle drive control systems not related to the control of a particular sub-unit related to ambient conditions
B60W 50/00 - Details of control systems for road vehicle drive control not related to the control of a particular sub-unit
A method of optimizing vehicle mobility performance includes receiving technical parameters for each wheel associated with wheel power of the particular wheel on a particular terrain. The method includes determining an optimal vehicle mobility performance by determining an optimal tire slippage for one wheel based on the set of technical parameters for the wheel and individually determining an optimal tire slippage for another wheel based on the set of technical parameters for the other wheel. A system may utilize such a method to control mobility performance in a vehicle such as, but not limited to, an autonomous ground vehicle.
G07C 5/02 - Registering or indicating driving, working, idle, or waiting time only
B60W 40/10 - Estimation or calculation of driving parameters for road vehicle drive control systems not related to the control of a particular sub-unit related to vehicle motion
78.
COMPOSITIONS AND METHODS OF REGENERATING HEART TISSUES WITH AMINOGLYCOSIDES
THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (USA)
THE UAB RESEARCH FOUNDATION (USA)
Inventor
Sadek, Hesham A.
Nguyen, Ngoc Uyen Nhi
Ahmed, Mahmoud Salama
Tomchick, Diana
Zhang, Jianyi
Abstract
Disclosures herein are directed to methods of regenerating cardiomyocytes in heart tissue damaged as a result heart failure in a subject by administering one or more aminoglycosides to a subject in need thereof. Accordingly, disclosures herein are also toward methods of administering one or more aminoglycosides to treat heart failure in a subject in need thereof.
A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
A61P 9/00 - Drugs for disorders of the cardiovascular system
THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (USA)
Inventor
Suto, Mark, J.
Mathew, Bini
Augelli-Szafran, Corinne, E.
Yatchang, Marina, Fosso
Athar, Mohammad
Agarwal, Anupam
Srivastava, Ritesh Kumar
Muzaffar, Suhail
Khan, Jasim
Abstract
The present disclosure is concerned with purine diamine compounds for the treatment of conditions associated with BRD4, RIP3K, and/or IL6 signaling dysfunction such as, for example, cancer (e.g., lung cancer, skin cancer, bladder cancer, kidney cancer, liver cancer), arsenicosis, arsenic poisoning, inflammation, skin lesions, dysfunction of systemic organs, and skin blisters. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
The United States Government as represented by the Department of Veterans Affairs (USA)
Inventor
Suto, Mark J.
Mathew, Bini
Augelli-Szafran, Corinne E.
Yatchang, Marina Fosso
Athar, Mohammad
Agarwal, Anupam
Srivastava, Ritesh Kumar
Muzaffar, Suhail
Khan, Jasim
Abstract
The present disclosure is concerned with purine diamine compounds for the treatment of conditions associated with BRD4, RIP3K, and/or IL6 signaling dysfunction such as, for example, cancer (e.g., lung cancer, skin cancer, bladder cancer, kidney cancer, liver cancer), arsenicosis, arsenic poisoning, inflammation, skin lesions, dysfunction of systemic organs, and skin blisters. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Various examples are provided related to blood-interface materials for metallic biomedical implants and devices. In one example, a bio-compatible implant or device includes an organosilane plasma polymerization (OPP) coating disposed on a surface of a metallic structure. The OPP coating can include inorganic silica disposed on bare metal of the metallic structure and forming a nano-textured surface. In another example, a biocompatible implant or device includes a composite coating disposed on a surface of the metallic structure. The composite coating can include silica-DEA, silica-MEA or silica-TEA coating disposed on bare metal of the metallic structure and forming a nano-textured surface. In another example, a method includes providing a metallic structure and exposing it to an OPP process to form a coating on the surface of the metallic structure to form the bio-compatible implant or device.
For many proteins, aggregation starts from phase separation, which frequently results from intermolecular interactions mediated by disordered protein regions. These disordered regions often contain repetitive sequences (also known as low-complex regions). In some embodiments, the protein solubilizing method described herein is applicable for proteins with the following two classes of repetitive sequences. Disclosed herein are mimic peptide sequences > 3 amino acids that can increase protein solubility of proteins having disordered protein regions.
C07C 323/60 - Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
The Board of Trustees of the University of Alabama (USA)
THE UAB RESEARCH FOUNDATION (USA)
Inventor
Sazonov, Eduard S.
Salas, Ariel A.
Chandler-Laney, Paula Catherine
Abstract
A feeding bottle includes a bottle enclosure defining a hollow bottle chamber, wherein the enclosure defines a feeding outlet at a first end and an attachment structure 26 at a second end. A bottom housing defines an instrument compartment extending between a closed exterior portion of the bottom housing and a separation surface within the bottom housing, wherein the bottom housing is configured for detachable connection to the attachment structure 26 of the bottle enclosure. A relief valve is positioned within the separation surface of the bottom housing. A pressure sensor is positioned adjacent the separation surface of the bottom housing and connected by a passageway to the instrument compartment in the bottom housing, wherein the pressure sensor is configured to detect changes of pressure in the bottle enclosure.
The present invention relates to methods, treatment regimens, uses, kits and therapies for prevention of graft rejection in solid organ transplantation, particularly solid organ xenotransplantation, by administering an anti-CD40 antibody or a combination of an anti-CD40 antibody and an anti-C5 antibody.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
86.
Substituted quinazoline sulfonamides as thioredoxin interacting protein (TXNIP) inhibitors
In one aspect, compounds and compositions that inhibit TXNIP expression and/or that lower hepatic glucose production and methods of identifying, making, and using same are disclosed. The disclosed compounds and compositions can be useful for disorders associated with elevated TXNIP and/or elevated glucagon levels such as, for example, diabetes and associated disorders. Further provided are methods for treating hyperlipidemia or fatty liver disease, optionally associated with elevated TXNIP and/or elevated glucagon levels. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Described herein are Dendrilla membranosa compounds and derivatives thereof. Also described herein are formulations that can contain an amount of one or more Dendrilla membranosa compounds or derivatives thereof and a carrier. Also described herein are methods of administering one or more Dendrilla membranosa compound and/or derivative thereof or a formulation thereof to a subject in need thereof.
A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
88.
RNA-BINDING PROTEIN MULTIMERIZATION INHIBITORS AND METHODS OF USE THEREOF
THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (USA)
Inventor
Nabors, Louis B.
Filippova, Natalia
Yang, Xiuhua
Ananthan, Subramaniam
Pathak, Vibha
King, Peter
Abstract
This disclosure provides compounds that inhibit RNA-binding proteins, such as Human antigen R protein (HuR). The compounds described herein have a high affinity for HuR multimers and inhibit the pathological processes that promote cancer and inflammation. The compounds are highly water-soluble and have good biodistribution for both systemic and central nervous system disease processes. The compounds provide a unique therapeutic option for disease processes related to neoplastic progression or acute or chronic inflammation.
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
The present disclosure describes system and methods for determining cardiac events from a physiological data signal and optionally constructing a Pressure-Volume (PV) loop display from non-simultaneously acquired measurements of pressure and volume data. One such method comprises obtaining, by a computing device, a physiological data signal of a heart of an individual; identifying, by the computing device, features of the physiological data signal and applying the features as inputs to a prediction model; determining, by the computing device using the prediction model, the cardiac events for one or more valves of the heart, wherein the cardiac events include timing of opening and closing of the one or more valves of the heart; and outputting, by the computing device, the cardiac events determined using the prediction model. The physiological data signal can be combined with non-simultaneously acquired volume data to create a PV loop display.
Relationships between morphological changes to an eye due to intraocular pressure changes and blood perfusion and nerve function changes in the retina are determined by colocalizing retinal perfusion data, optic nerve head (ONH) mechanical deformation data, visual field data and nerve fiber data. Perfusion and nerve function changes from intraocular pressure (IOP) changes are determined by colocalizing retinal perfusion data with ONH mechanical deformation data, visual field data and nerve fiber data. Optical coherence tomography-angiography (OCT-A) can be used to generate retinal perfusion data, mechanical deformation data for an imaged volume, and nerve fiber data. A three-dimensional model (e.g., connectivity map or connectivity model) of the vasculature and nerve fibers can be generated from the OCT-A imaging data and used to predict changes in blood perfusion and nerve function in various areas of the retina due to IOP-induced mechanical deformations.
A61B 3/12 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes
A61B 3/00 - Apparatus for testing the eyesInstruments for examining the eyes
G06T 7/33 - Determination of transform parameters for the alignment of images, i.e. image registration using feature-based methods
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
91.
METHODS AND FORMULATIONS RELATED TO THE INTRATHECAL DELIVERY OF ONCOLYTIC VIRUSES
A method of treating a central nervous system cancer in a subject comprising administering to the subject a preconditioning agent, and, administering to the subject a therapeutic dose of an oncolytic virus; wherein the preconditioning agent is an immunostimulant selected from the group consisting of a toll-like receptor agonist, a subtherapeutic dose of an oncolytic virus, and/or an interferon that induces a transient anti-viral response and/or upregulates an interferon response; and wherein the preconditioning agent and the therapeutic dose of the oncolytic virus is administered to the subject's cerebrospinal fluid or periependymal region. Provided herein are methods of treating a central nervous system cancer in a subject. This method allows for intrathecal administration of oncolytic virus, which, until the present invention, resulted in unacceptable toxicity.
A61K 35/768 - Oncolytic viruses not provided for in groups
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
In one aspect, the disclosure relates to nanoparticle compositions including TT-10 or a pharmaceutically acceptable salt thereof and nanoparticles including at least one biocompatible polymer or copolymer such as poly-lactic-co-glycolic acid. Also disclosed are methods for improving at least one cardiac function or property following heart damage in a subject, the methods including at least the step of administering the nanoparticle compositions to the subject. In another aspect, the nanoparticle compositions can be administered by intraperitoneal injection and are active at a target site for a period of at least 4 weeks.
A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Disclosed is a method for reducing metastasis and/or tumor growth in a subject with cancer by administering an effective amount of an inhibin antibody to the subject with cancer. In particular, the subject may have ovarian cancer and the administration of inhibin antibody may impair tumor growth.
Methods for using BMP9 or an agonist thereof to reduce metastasis of cancer are disclosed. The method may include administering an effective amount of BMP9 or an agonist thereof to a subject in need thereof, to reduce metastasis of cancer. The subject may be a human.
The present invention relates to methods, treatment regimens, uses, kits and therapies for prevention of graft rejection in solid organ transplantation, particularly solid organ xenotransplantation, by administering an anti-CD40 antibody or a combination of an anti-CD40 antibody and an anti-C5 antibody.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
A61K 39/00 - Medicinal preparations containing antigens or antibodies
97.
HUMAN NEUTRALIZING ANTIBODIES AGAINST SARS-COV-2 SPIKE S2 DOMAIN AND USES THEREOF
The disclosure is based, at least in part, on certain human monoclonal antibodies, or antigen binding fragments thereof, having unexpected broad neutralizing activities against SARS-CoV-2. The disclosed antibodies and/or antigen-binding fragments thereof are therapeutic agents for the treatment of SARS-CoV-2 infections and are suitable for use in therapeutic methods to protect individuals from SARS-CoV-2 infections.
Royal Holloway and Bedford New College, (United Kingdom)
Inventor
Wallis, Deeann
Kesterson, Robert
Korf, Bruce
Leier, Andre
Lambert, Laura
Popplewell, Linda
Dickson, George
Abstract
The present disclosure provides methods and compositions for the treatment of NF-1 and NF-1 mediated conditions. The present disclosure further provides for methods of exon skipping and exon retention and compositions for use in such methods. Such methods of exon skipping and exon retention may be used in the methods of treatment discussed herein. The present disclosure further provides new therapeutic compounds, particularly oligonucleotides, including antisense oligonucleotides, for use in the methods described herein.
Disclosed is an antibody that selectively binds CD47 on tumor cells. Also disclosed is a method for treating cancer in a subject, comprising administering to the subject an effective amount of the antibody disclosed.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
A method for preventing wrong-patient errors includes receiving a selection of a current imaging subject. The current imaging subject is selected for a current image acquisition session comprising capturing one or more current images of the current imaging subject utilizing at least a first image sensor system of a first imaging modality. The method includes accessing one or more previous images of a previous imaging subject. The one or more previous images depict the previous imaging subject according to at least a second imaging modality that is different from the first imaging modality. The method includes presenting the one or more previous images on a display system and, in response to determining that the previous imaging subject matches the current imaging subject based upon the one or more previous images, performing the current image acquisition session.
